When was TScan Therapeutics founded?

TScan Therapeutics was founded in 1995 and raised its 1st funding round 24 years after it was founded.

Where is TScan Therapeutics located?

TScan Therapeutics is headquartered in Boston, United States. It is registered at Waltham, Massachusetts.

Who is the current CEO of TScan Therapeutics?

David P. Southwell of TScan Therapeutics.

How many employees does TScan Therapeutics have?

As of Sep 30, 2026, the latest employee count at TScan Therapeutics is 139.

Is TScan Therapeutics a funded company?

TScan Therapeutics is a funded company, having raised a total of $180M across 3 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jul 24, 2019.

When was the latest funding round of TScan Therapeutics?

TScan Therapeutics' latest funding was a $***** Series C round on Jan 25, 2021, with participation from 8 investors.

Where does TScan Therapeutics rank among its competitors?

TScan Therapeutics ranks 5th amongst 861 active competitors, of which 341 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of TScan Therapeutics?

TScan Therapeutics' top competitors include Sana Biotechnology, Immuneel and Abcellera Biologics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

TScan Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

TScan Therapeutics is a public company based in Boston (United States), founded in 1995 by Lea Hachigian. It operates as a Developer of T cell therapies to harness the immune system against cancer. TScan Therapeutics has raised $180M in funding from investors like Pitango, BlackRock and Novartis. The company has 861 active competitors, including 341 funded and 188 that have exited. Its top competitors include companies like Sana Biotechnology, Immuneel and Abcellera Biologics.

Company Details

Developer of T cell therapies to harness the immune system against cancer. The company focuses on hematologic malignancies and solid tumors using proprietary platforms like TargetScan and ReceptorScan. The company's product line include TSC-100 and TSC-101 target residual disease in AML, MDS, and ALL patients post-allogeneic hematopoietic cell transplant.

Website: www.tscan.com/
Social
Email ID: *****@tscanrx.com
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

1995

Location

Boston, United States

Stage

Public

Total Funding

$180M in 3 rounds

Latest Funding Round

Series C, Jan 25, 2021, $*****

Investors

Pitango & 10 more

Ranked

5^th among 861 active competitors

Employee Count

139 as on Sep 30, 2026

Similar Companies

Sana Biotechnology & 1011 more

Exit Details

Public

View TScan Therapeutics' full profile

TScan Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Tscan Therapeutics, Inc. CIN: 82-5282075 , United States, Active	Apr 16, 2018	-	154 (As on Dec 31, 2023)	-
TSCAN THERAPEUTICS INC. CIN: 825282075 , United States, Active	Dec 26, 999	-	188 (As on Dec 31, 2024)	-

TScan Therapeutics got listed on Jul 16, 2021.

Click here to take a look at TScan Therapeutics's IPO in detail

TScan Therapeutics has raised a total funding of $180M over 3 rounds. Its first funding round was on Jul 24, 2019. Its latest funding round was a Series C round on Jan 25, 2021 for $*****. 8 investors participated in its latest round. TScan Therapeutics has 11 institutional investors.

Here is the list of recent funding rounds of TScan Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 25, 2021	1076834	Series C	6747378	9837459	3709774	9854621
Jan 09, 2020	2241714	Series B	3082719	8931430	7130510	Novartis & 4 more
Jul 24, 2019	7051147	Series B	8468817	4081251	Novartis	Google Ventures & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of TScan Therapeutics's funding rounds and investors

The founders of TScan Therapeutics is Lea Hachigian.

Here are the details of TScan Therapeutics' key team members:

Lea Hachigian: Co-Founder & President of TScan Therapeutics and founder of 1 other company.
David P. Southwell: CEO of TScan Therapeutics.

View details of TScan Therapeutics's Founder profiles and Board Members

TScan Therapeutics' employee count trend

TScan Therapeutics has 139 employees as of Sep 26. Here is TScan Therapeutics's employee count trend over the years:

Employee count trend for TScan Therapeutics

Uncover TScan Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TScan Therapeutics include Sana Biotechnology, Immuneel and Abcellera Biologics. Here is the list of Top 10 competitors of TScan Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
2nd	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
4th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
5th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, K2 HealthVentures & 9 others	62/100
6th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 2 others	69/100
7th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	67/100
8th	Immatics 2000, Tubingen (Germany), Public	Developer of T -cell-based immunotherapies for the treatment of cancer	$236M	Wellington Partners Venture Capital, Dievini ... & 18 others	67/100
9th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
10th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	67/100